Showing results (61-70 of 93) with videos related to

Sort By:
Pageof 10
Biorxiv : the Preprint Server for Biology|February 17, 2023
STAT3 protects HSCs from intrinsic interferon signaling and loss of long-term blood-forming activityBhakti Patel, Yifan Zhou, Rachel L Babcock, et al.
American Journal of Hematology|January 12, 2017
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agentsElias Jabbour, Paolo Strati, Monica Cabrero, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2023
Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in RAS -mutated chronic myelomonocytic leukemiaGuillermo Montalban-Bravo, Feiyang Ma, Natthakan Thongon, et al.
The Lancet. Haematology|September 5, 2022
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 studyAlexandre Bazinet, Faezeh Darbaniyan, Elias Jabbour, et al.
Blood Cancer Journal|March 28, 2026
Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromesAlexandre Bazinet, Alex Bataller, Kelly Chien, et al.
Blood Advances|March 24, 2019
NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapyGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Koji Sasaki, et al.
Nature|August 17, 2012
Passenger deletions generate therapeutic vulnerabilities in cancerFlorian L Muller, Simona Colla, Elisa Aquilanti, et al.
Leukemia|March 12, 2024
STAT3 protects hematopoietic stem cells by preventing activation of a deleterious autocrine type-I interferon responseBhakti Patel, Yifan Zhou, Rachel L Babcock, et al.
Cancer Discovery|July 4, 2012
microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastomaGiannicola Genovese, Ayla Ergun, Sachet A Shukla, et al.
The Lancet. Haematology|February 5, 2024
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 studyAlex Bataller, Guillermo Montalban-Bravo, Alexandre Bazinet, et al.
Pageof 10